<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3123">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696601</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-27</org_study_id>
    <nct_id>NCT04696601</nct_id>
  </id_info>
  <brief_title>Rapid Screening for Olfactory Disorders in Covid-19 Infection</brief_title>
  <acronym>OLFASCAN</acronym>
  <official_title>Rapid Screening for Olfactory Disorders in Covid-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Loss of smell is very frequently found in Europe during Covid-19 attack. This symptom was not&#xD;
      initially expected as part of the classic symptomatology. This loss of smell mainly concerns&#xD;
      patients with few or no symptoms, without criteria of severity and usually treated on an&#xD;
      outpatient basis. As a result, given the unexpected occurrence of this symptom (with less&#xD;
      awareness in the general and medical population) and the potential risk of contamination of&#xD;
      Covid+ and anosmic subjects (due to their less symptomatic form), it is interesting to be&#xD;
      able to propose large-scale screening for loss of sense of smell in order to preferentially&#xD;
      direct subjects diagnosed as anosmic towards RT-PCR-type screening. In the medium term, the&#xD;
      loss of smell seems to persist after the infectious phase, with delayed or persistent&#xD;
      recovery, which can lead to negative psychological repercussions.&#xD;
&#xD;
      The objective is to propose large-scale screening of the general population for loss of sense&#xD;
      of smell during a pandemic period, in order to facilitate diagnostic orientation of the&#xD;
      population. The diagnosis of loss of smell will be carried out using a simple olfactory test&#xD;
      in the form of an olfactory stick to be smelled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2021</start_date>
  <completion_date type="Anticipated">February 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Olfactory test</measure>
    <time_frame>Day 0</time_frame>
    <description>Sensitivity of the olfactory test (Olfascan) for measuring anosmia, compared to the reference diagnostic test (RT-PCR analysis).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Olfaction Disorders</condition>
  <condition>COVID-19 Testing</condition>
  <arm_group>
    <arm_group_label>Olfactory test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The result of the olfactory test will be compared to the result of the RT-PCR test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Olfactory test</intervention_name>
    <description>The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.</description>
    <arm_group_label>Olfactory test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject presenting himself at the covid-19 screening centre set up by the city of Nice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a sensory deficit (auditory or visual) preventing the subject from&#xD;
             answering the questions perfectly during the olfactory test.&#xD;
&#xD;
          -  Subject receiving cancer chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud DAVID, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud DAVID, Dr</last_name>
    <phone>4 92 03 43 99</phone>
    <phone_ext>+33</phone_ext>
    <email>david.r@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Renaud DAVID, Dr</last_name>
      <phone>4 92 03 43 99</phone>
      <phone_ext>+33</phone_ext>
      <email>david.r@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Olfaction Disorders</keyword>
  <keyword>Hyposmia</keyword>
  <keyword>Dysosmia</keyword>
  <keyword>Anosmia</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olfaction Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

